weight loss drug zepbound

Weight Loss Drug Demand Drives Eli Lilly Sales

Zepbound sales keep soaring, even as weight loss drug growth slows

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s initial sales expectations.

Hosted on MSN · 23h

Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soared. The company's quarterly earnings topped Wall Street estimates,

Reuters · 2d

Lilly needs a plan to spur weight-loss drug sales, investors say

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month forecast lower-than-expected fourth-quarter revenues for the drug.

Zepbound sales double, tariffs could hit Ozempic, and Pfizer on RFK Jr.: Pharma news roundup

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite ...

ConsumerAffairs1h

Here are the health pros and cons of GLP-1RA weight loss drugs

New GLP-1RA weight loss drugs like Like Ozempic and Wegovy have become extremely popular in recent months but researchers ...

21hon MSN

Lilly’s Mounjaro and Zepbound contribute to big revenue boost, drugmaker says

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

4don MSN

Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results